Skip to main content

Table 2 Clinical characteristics

From: Association between methadone dose and concomitant cocaine use in methadone maintenance treatment: a register-based study

Variables

Low dose group (LDG) (n = 200)

Medium dose group (MDG) (n = 273)

High dose group (HDG) (n = 140)

Total sample (N = 613)

p value

Specialized centers, n (%)a

114 (57.0)

189 (69.2)

104 (74.3)

407 (66.4)

p < 0.01

Methadone dose mg/ day, mean (SD)b

35.0 (±12.1)

81.3 (±14.8)

150.0 (±33.3)

81.9 (±46.6)

p < 0.001

Prescribed comedication, n (%)c

77 (38.7)

164 (60.1)

108 (77.1)

349 (57.0)

p < 0.001

Allowed take-home days per week, mean (SD)d

5.8 (±3.7)

5.1 (±3.2)

4.5 (±2.7)

5.2 (±3.3)

p < 0.001

Length of stay in MMT, mean (SD), ye

9.3 (±4.5)

10.2 (±4.7)

11.3 (±4.8)

10.2 (±4.7)

p < 0.001

No. of consultations within 6 months, mean (SD)f

5.9 (±4.2)

6.2 (±4.2)

7.7 (±6.7)

6.4 (±4.9)

p < 0.01

Alcohol use in the past 30 days, mean (SD)g

7.4 (±11.1)

8.9 (±11.1)

11.8 (±13.3)

9.1 (±12.1)

p < 0.01

Cannabis use in the past 30 days, mean (SD)h

8.5 (±12.1)

8.9 (±12.0)

11.8 (±13.3)

8.3 (±11.2)

p > 0.05

  1. Significance level p < 0.05.
  2. aSignificant difference between patients in the LDG, MDG and HDG (Kruskal-Wallis test; χ2 = 12.782; df = 2; p < 0.01). The Mann Whitney test revealed that patients in the LDG were significantly more often treated in office-based settings than patients in the MDG (Z = −2.736; p < 0.01) or in the HDG (Z = −3.266; p < 0.001).
  3. bSignificant difference between patients in the LDG, MDG and HDG for prescribed methadone dose (ANOVA; F(2,610) = 1343.158; p < 0.001).
  4. cSignificant difference between patients in the LDG, MDG and HDG (Kruskal-Wallis test; χ2 = 51.360; df = 2; p < 0.001). The Mann Whitney test revealed that patients in the LDG had a significantly lower proportion of prescribed comedication than patients in the MDG (Z = −4.584; p < 0.001) or in the HDG (Z = −6.990; p < 0.001).
  5. dSignificant differences between patients in the LDG, MDG and HDG for allowed take-home methadone days per week (ANOVA; F(2,603) = 6.750; p < 0.001). Post-hoc tests (Duncan Scheffé’s) revealed that patients in the HDG had significantly fewer take-home days than patients in the LDG (p < 0.001) but not in the MDG (p > 0.05).
  6. eSignificant differences between patients in the LDG, MDG and HDG for length of stay in MMT (ANOVA; F(2,611) = 7.734; p < 0.001). Post-hoc tests (Duncan Scheffé’s) revealed that patients in the HDG had a significantly longer length of stay in MMT than patients in the LDG (p < 0.001) but not in the MDG (p > 0.05).
  7. fSignificant differences between patients in the LDG, MDG and HDG for the number of consultations in the past 6 months (ANOVA; F(2,603) = 5.907; p < 0.01). Post-hoc tests (Duncan Scheffé’s) revealed that patients in the HDG had significantly more consultations than patients in the LDG (p < 0.01) or in the MDG (p < 0.05).
  8. gSignificant differences between patients in the LDG, MDG and HDG for alcohol use in the past 30 days (ANOVA; F(2,598) = 5.087; p < 0.01). Post-hoc tests (Duncan Scheffé’s) revealed that patients in the HDG had significantly more alcohol consumption days than patients in the LDG (p < 0.01) but not in the MDG (p > 0.05).
  9. hNo differences between patients in the LDG, MDG and HDG for cannabis use in the past 30 days (ANOVA; F(2,604) = 0.160; p > 0.05).
Back to article page

Substance Abuse Treatment, Prevention, and Policy

ISSN: 1747-597X